Crestwood Advisors Group LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 7,350.2% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 432,409 shares of the company's stock after purchasing an additional 426,605 shares during the period. Crestwood Advisors Group LLC's holdings in AstraZeneca were worth $31,782,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in AZN. Bank of America Corp DE raised its holdings in AstraZeneca by 189.3% during the fourth quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock worth $1,574,247,000 after purchasing an additional 15,722,197 shares in the last quarter. Marshall Wace LLP acquired a new position in AstraZeneca in the fourth quarter worth approximately $254,018,000. Alyeska Investment Group L.P. grew its position in AstraZeneca by 220.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 3,027,511 shares of the company's stock worth $198,363,000 after buying an additional 2,083,645 shares during the last quarter. Point72 Asset Management L.P. grew its position in AstraZeneca by 815.8% in the fourth quarter. Point72 Asset Management L.P. now owns 1,073,630 shares of the company's stock worth $70,344,000 after buying an additional 1,223,630 shares during the last quarter. Finally, Alliancebernstein L.P. grew its position in AstraZeneca by 65.1% in the fourth quarter. Alliancebernstein L.P. now owns 3,101,025 shares of the company's stock worth $203,179,000 after buying an additional 1,222,669 shares during the last quarter. Institutional investors own 20.35% of the company's stock.
AstraZeneca Trading Up 1.1%
NASDAQ AZN traded up $0.79 on Thursday, hitting $73.79. 3,943,989 shares of the stock were exchanged, compared to its average volume of 5,235,186. AstraZeneca PLC has a 52-week low of $61.24 and a 52-week high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70. The company has a market capitalization of $228.86 billion, a price-to-earnings ratio of 29.64, a P/E/G ratio of 1.30 and a beta of 0.37. The company's 50-day moving average price is $70.96 and its two-hundred day moving average price is $71.02.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.10 by $0.14. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. During the same period in the previous year, the company posted $2.06 EPS. The company's quarterly revenue was up 7.2% compared to the same quarter last year. Research analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.
Wall Street Analysts Forecast Growth
Several research firms have issued reports on AZN. Berenberg Bank set a $97.00 price target on shares of AstraZeneca in a research report on Wednesday, July 9th. BNP Paribas began coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 price target on the stock. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $89.00.
Check Out Our Latest Report on AstraZeneca
About AstraZeneca
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Articles
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
